McKesson Corporation
MCK
Delayed Nyse - 12/14 10:04:58 pm
157.2USD
+1.28%

McKesson : ALUNBRIG (brigatinib) Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.

Envoyer par e-mail
05/11/2017 | 03:11 pm

CARY, N.C. (May 11, 2017) -Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc., to be a specialty pharmacy provider as part of the distribution network for ALUNBRIG(brigatinib).

ALUNBRIG, an oral therapy for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib, received Accelerated Approval by the U.S. Food and Drug Administration (FDA) on April 28, 2017. This Accelerated Approval was based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ALUNBRIG previously received Breakthrough Therapy Designation and was granted Orphan Drug Designation by the FDA.

NSCLC is the most common form of lung cancer, making up 85% of new lung cancer cases in the U.S. each year. Approximately 2-8% of these patients have a rearrangement in the ALK gene.

'We are thrilled to have been given the privilege of being in this network of specialty pharmacies dispensing ALUNBRIG,' said Brandon Tom, vice president, Biopharma Services, Biologics, Inc. 'Our team has decades of experience supporting NSCLC patients. We're well prepared to help patients transition to this new therapy and to support them throughout their entire treatment journey.'

ALUNBRIG is manufactured by Takeda Pharmaceutical Company Limited through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc. Full prescribing information for ALUNBRIG is available at www.ALUNBRIG.com.

Biologics' oncology specialty pharmacy is supported by a multidisciplinary care team that includes a pharmacist, oncology nurse and financial counselor. Individualized care plans are developed to address the unique needs of each patient and to streamline communication back to the treating provider.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics

Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes - clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient's best interest as the surest path to managing cost and risk.

Biologics is part of McKesson Specialty Health, a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit www.mckessonspecialtyhealth.com and www.biologicsinc.com.

PR Contact

Claire Crye
281-825-9927
[email protected]

McKesson Corporation published this content on 11 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 May 2017 13:11:17 UTC.

Envoyer par e-mail